Illumina
Illumina, Inc., a leading player in the genomics industry, is headquartered in the United States, with significant operations across Europe and Asia. Founded in 1998, Illumina has revolutionised DNA sequencing and array-based solutions, making substantial contributions to genomic research and personalised medicine. The company’s core products include advanced sequencing systems, reagents, and bioinformatics tools, which are distinguished by their high throughput and accuracy. Illumina's innovative technologies have positioned it at the forefront of the market, enabling researchers and clinicians to unlock the complexities of the genome. With numerous accolades and a robust portfolio, Illumina continues to drive advancements in genomics, supporting initiatives in healthcare, agriculture, and environmental science. Its commitment to innovation and quality has solidified its reputation as a trusted partner in the life sciences sector.
DitchCarbon Score
How does Illumina's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Illumina's score of 89 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Illumina's reported carbon emissions
In 2024, Illumina reported total greenhouse gas emissions of approximately 18836000 kg CO2e for Scope 1 and about 21224000 kg CO2e for Scope 2 globally. In the US, their emissions included around 18098000 kg CO2e for Scope 1 and about 7852000 kg CO2e for Scope 2. The company has not disclosed Scope 3 emissions for the US region. Illumina has set ambitious climate commitments, aiming for a 46% reduction in absolute Scope 1 and 2 emissions by 2030 from a 2019 baseline. Additionally, they plan to achieve net-zero greenhouse gas emissions across all operations (Scopes 1, 2, and 3) by 2050. This includes a commitment to source 100% renewable electricity by 2030. The company’s long-term targets include a 90% reduction in absolute Scope 1 and 2 emissions by 2050, alongside a similar reduction for Scope 3 emissions. These initiatives reflect Illumina's dedication to sustainability and its proactive approach to addressing climate change within the biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 6,317,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 37,165,000 | 00,000,000 | 00,000,000 | 0,000,000 | - | - | 00,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Illumina is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
